So F15 continues to gain in popularity. Product is working great, people are highly satisfied with the product. And we’re okay either way. As long as they’re doing business with Axonics, we’re happy to get the business regardless of which device they want to implant.
Operator: Our next question comes from Shagun Singh with RBC Capital Markets. I do apologize, his line did disconnect. The next question comes from Mike Matson with Needham & Company.
Mike Matson: Yes, thanks. Great to see the continued strength with Bulkamid. I was just wondering if in terms of the R&D pipeline, is there any opportunity to create enhancements, reformulations of that product? And are there any opportunities for indication expansions or maybe going into additional international markets?
Raymond Cohen: So with respect to Bulkamid, we have a pretty robust business internationally, Mike. In fact, I think it was 81% of the Bulkamid revenue? You guys checking me on this number?
Kari Keese: It’s 19% international.
Raymond Cohen: 19% international, so 81% in the United States. So almost 20% of the business in the quarter came from international markets and we’re selling in quite a few countries; so that will continue. At the moment, Mike, we got heads down. We’re just focused on continued adoption and utilization of Bulkamid. We are — our pants are not on fire to try to do more things with that product. It’s going really well. And I think the key thing for us now is just kind of continuing to get the word out on the product and it’s fast becoming first-line therapy for women with stress urinary incontinence. So I think that pretty well answers the question as directly as I can.
Operator: The next question comes from David Rescott with Baird.
David Rescott: Congrats on the strong quarter here. Ray, you — I think in the prepared remarks, you called out a modest increase in head count heading into 2024. Not necessarily eternally sure where the Street is for next year but we’re kind of in that mid-teens OpEx growth outlook into 2024. I’m just wondering if you could provide any more color on really how you’re thinking about or qualifying this modest increase in headcount next year?
Raymond Cohen: Well, I would say modest is probably in the neighborhood of 5% or so. I mean if it was 10%, it’s not so modest, right? But we’re covering literally the entire United States. I mean, we don’t have areas of the country where we don’t have representation. I mean we even — maybe Alaska is last remaining state in the union. We have a representative now in Hawaii selling both Bulkamid and sacral neuromodulation. So we’ve got good coverage — but we are now doubling down in certain territories around the United States where for one reason or another, our competitor may have more business than we do, that we’re not getting our fair share and those are the markets that we’re really looking to invest more in terms of personnel.
So we make sure we call on all those folks that are not doing business with us. So what I would say is that we have very good data at this point. We know exactly who’s doing sacral neuromodulation in the United States. We know from third-party billing data how many procedures they’re doing. We know a lot of stuff that we just didn’t have this information years ago. So we’re pretty focused now. And the key thing for us is that we want to bring some bigger users, if you may, people that have higher volume to the party, that really helps move the meter. So I think at this point, considering we’re less than — well, we’re almost 4 years now, almost 4 years now commercial in the United States, that I think we’ve made phenomenal progress during this period of time.
And I’m really excited about the next 18 to 24 months and what we can accomplish during that period.
